 Amyris Inc NASDAQ: AMRS and ImmunityBio NASDAQ: IBRX have completed their previously announced joint venture agreement to accelerate the commercialization of a next-generation COVID-19 vaccine. Upon completion of human trials and regulatory approval, the joint ventures goal is to start delivering the second-generation vaccine in 2022 as soon as it is practically possible to deliver. 